Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome: a Multicentre, Randomized, Double-blind, Parallel-group, Placebo-controlled Study

NCT06681012 is registered in ClinicalTrials.gov with Devintec Sagl as lead sponsor.

NCT NCT06681012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06681012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome: a Multicentre, Randomized, Double-blind, Parallel-group, Placebo-controlled Study
Lead sponsor
Devintec Sagl
Phase
Not applicable
Overall status
Recruiting
Start date
October 22, 2024
Completion date
July 31, 2027
Enrollment
330 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome (ibs), irritable bowel syndrome of diarrhea type (ibs-d)